Elanco Animal Health stock falls 3.63 percent as Jefferies cuts target

Published on 10/20/2026 at 21:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 1.37 billion in the second quarter. Elanco stock costs EUR 20.15 on October 20, 2026, down 3.63 percent versus Tradegate close.

Analyst target and earnings

Jefferies cut its Elanco target from USD 31.00 to USD 24.00 on October 19, 2026.
Second-quarter revenue reached USD 1.37 billion, up 10.20 percent year over year.
Elanco stock was trading at EUR 20.15 at Lang & Schwarz on October 20, 2026 at 9:01 p.m. CEST, down 3.63 percent versus the Tradegate close of October 16, 2026.

ELAN, US28414H1032, Illustration mit AI erstellt.

Jefferies downgraded Elanco Animal Health from Buy to Hold and cut its price target from USD 31.00 to USD 24.00 on October 19, 2026. According to Investing.com, analyst Keith Devas cited pricing risks in animal health. Elanco Animal Health stock was trading at EUR 20.15 at Lang & Schwarz on October 20, 2026 at 9:01 p.m. CEST, down 3.63 percent versus the Tradegate close of October 16, 2026 at EUR 20.91.

Pricing risk meets fresh growth

The downgrade contrasts with Elanco's latest operating figures. In the second quarter of 2026, revenue reached USD 1.37 billion, up 10.20 percent from the same quarter of 2025, while adjusted earnings per share came to USD 0.34 against a USD 0.27 consensus estimate, according to Investing.com. The earnings figure exceeded consensus by USD 0.07.

Jefferies sees volume, rather than pricing, as the main growth driver through 2026. Its base case assumes 4.00 percent annual growth from 2026 through 2028, while the reduced pricing contribution supports 8.00 percent earnings-per-share growth, below Elanco's double-digit target.

Stock remains inside its yearly range

Elanco's NYSE price was USD 22.61 at 7:03 p.m. UTC on October 20, 2026. The stock's 52-week range was USD 19.40 to USD 27.98, leaving the euro quote below the upper end of the dollar range only as a separate currency reference. Market capitalization stood at USD 11.3 billion, and trading volume reached 5,715,199 shares.

Results date sets the next marker

Elanco is scheduled to report third-quarter 2026 results on November 6, 2026, at 8:00 a.m. Eastern time, according to the company's Elanco investor relations page. The date gives investors a near-term test for whether volume growth can offset the pricing pressure highlighted by Jefferies.

What matters for valuation?

Elanco's negative trailing price-to-earnings ratio reflects recent losses rather than a conventional earnings multiple. The next results will therefore matter for the USD 24.00 target, the USD 1.10 to USD 1.16 full-year 2026 adjusted earnings-per-share guidance, and the company's ability to convert revenue growth into profit.

Tradegate reference sets the daily view

The sharp daily decline places the Lang & Schwarz indication below the October 16, 2026 Tradegate close, while the primary listing remains the NYSE. The comparison is a market snapshot, not a forecast.

The further course of trading is shown by the continuously updated real-time quote of Elanco Animal Health stock.